Home » Stocks » Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc. (PGNX)

Jun 19, 2020 - PGNX was delisted (reason: acquired by LNTH)
Stock Price: $4.10 USD -0.43 (-9.49%)
Updated Jun 19, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 355.04M
Revenue (ttm) 36.95M
Net Income (ttm) -66.62M
Shares Out 86.60M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jun 19, 2020
Last Price $4.10
Previous Close $4.53
Change ($) -0.43
Change (%) -9.49%
Day's Open -
Day's Range 3.94 - 4.79
Day's Volume 0
52-Week Range 1.89 - 6.37

More Stats

Market Cap 355.04M
Enterprise Value 378.37M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 86.60M
Float 68.10M
EPS (basic) -0.77
EPS (diluted) -0.77
FCF / Share -0.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.76M
Short Ratio 9.30
Short % of Float 9.27%
Beta 1.98
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.61
PB Ratio 11.60
Revenue 36.95M
Operating Income -64.09M
Net Income -66.62M
Free Cash Flow -74.08M
Net Cash -23.32M
Net Cash / Share -0.27
Gross Margin 86.10%
Operating Margin -173.45%
Profit Margin -180.30%
FCF Margin -200.47%
ROA -29.18%
ROE -116.89%
ROIC -80.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.50*
Low
6.50
Current: $4.10
High
6.50
Target: 6.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue34.9915.6211.7069.438.6844.387.8614.0584.807.95
Revenue Growth123.95%33.54%-83.15%700.24%-80.45%464.45%-44.03%-83.43%966.35%-
Gross Profit31.8215.6211.7069.438.6844.387.8614.0584.807.95
Operating Income-65.24-72.16-55.808.50-37.704.87-43.18-35.4910.32-69.88
Net Income-68.55-67.66-51.0110.81-39.114.41-42.57-35.4310.38-69.73
Shares Outstanding85.6177.8970.2870.0069.7268.1955.8034.7533.3832.59
Earnings Per Share-0.80-0.87-0.730.15-0.560.06-0.76-1.020.31-2.14
Operating Cash Flow-74.70-46.75-54.1119.52-40.1413.73-36.11-34.6418.39-46.41
Capital Expenditures-15.23-0.82-0.23-3.94-0.32-0.570.04-0.38-0.23-2.17
Free Cash Flow-89.93-47.57-54.3415.58-40.4613.16-36.07-35.0218.16-48.58
Cash & Equivalents42.0513890.6413974.1011965.8658.8470.1147.92
Total Debt54.6344.6049.6949.45------
Net Cash / Debt-12.5893.0940.9689.4674.1011965.8658.8470.1147.92
Assets11916914619913116111576.3180.1162.74
Liabilities72.9268.4282.5094.2240.5936.1335.569.748.3111.43
Book Value46.5510163.4510590.4612578.9866.5771.8051.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Progenics Pharmaceuticals, Inc.
Country United States
Employees 105
CEO David W. Mims

Stock Information

Ticker Symbol PGNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PGNX
IPO Date November 19, 1997

Description

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.